Invested through |
|
---|---|
Asset Classes | Listed equity |
Impact strategy | Impact Equities and Bonds |
Bloomberg ticker | ARE US |
ISIN code | US0152711091 |
Industry group | Real estate |
Aligned with SDGs |
Alexandria Real Estate Equities owns, develops, and operates offices and labs to life science tenants, including biotech and pharmaceutical companies, universities, research institutions, medical office developers, and government agencies. As real estate investment trust (REIT), Alexandria owns well over 400 specialised properties in the US and Canada. Its portfolio is largely located in high-tech hotbeds such as Greater Boston, New York City, the San Francisco Bay area, San Diego, Seattle, Maryland, and Research Triangle. The company was founded in 1994.
Investment rationale
By offering high-quality lab and office space Alexandria Real Estate Equities supports the burgeoning demand for medical innovation driven by an aging US population. Alexandria hosts around 1,000 tenants, including major pharmaceutical companies, biotech firms, medical device companies, digital health, and research institutions. These tenants focus on disease prevention, diagnosis, and treatment. By providing top-tier facilities, Alexandria supports a robust health system that enhances well-being, mitigates the impact of ill-health, and ensures broad access to healthcare innovations.
Many of Alexandria's tenants prefer sustainable buildings, with 90% of its top tenants aiming for net-zero carbon or neutrality. Its leases include green clauses to promote sustainability. Alexandria reduces emissions through electrification, energy efficiency, and renewable electricity while also using low-carbon materials. It sets goals for energy, water, and waste efficiency and follows a climate resilience roadmap. Its cluster development strategy promotes alternative transportation, offering bike shares, EV charging, and shuttles to mass transit.